News Details

Important addition to CVC portfolio gives clinicians added convenience and confidence in the placement of Centrally-Inserted Central Catheters when taking maximal sterile barrier precautions

WAYNE, Pa., December 10, 2024 – Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the launch of its new Pressure Injectable Arrowg+ard Blue Plus™ MSB Procedure Kit in Europe, the Middle East and Africa. The Arrow™ MSB Procedure Kit is a significant addition to Teleflex's market-leading portfolio of Centrally-Inserted Central Catheters.^1,3

Following extensive market research and feedback from leading vascular access professionals, the Arrow™ MSB Procedure Kit provides clinicians with the components they need while adhering to maximal sterile barrier precautions. The Kit includes these key components, some of which are exclusive:

• Pressure Injectable CVC impregnated with Arrowg+ard Blue Plus™ Protection
• The Arrow™ GlideWheel™ Advancer, which provides tactile feedback and finer control
• The new dilator, which has demonstrated a reduction of penetration force by 48% to 72% when compared to a standard dilator²
• Nitinol Guidewire, which is kink-resistant compared to stainless steel
• Transducer Cover and other critical items which together provide the clinician with the tools needed for taking maximal sterile barrier precautions¹ as recommended in a range of respected clinical guidelines

“The Arrow™ MSB Procedure Kit reflects Teleflex’s commitment to advancing patient safety. It has been designed through a process involving rigorous analysis of over 1000 customized kits, detailed review of and alignment with authoritative clinical guidelines, and comprehensive market research." Said Hayleigh Haggerty, Clinical Affairs Director, Vascular EMEA (Europe, Middle East & Africa). “These new additions will contribute to the safety of critically ill patients by providing clinicians in one kit with all the components they need in the placement of Centrally-Inserted Central Catheters. It may also promote clinician confidence in the devices they use. This important addition to the Pressure Injectable Arrowg+ard Blue Plus™ CVC portfolio supports high safety standards and consistent patient care, helping drive the ongoing effort to reduce CLABSI risk.¹”

With 28.4% of healthcare-associated bloodstream infections reported as CVC-related according to the European Centre for Disease Prevention and Control (ECDC), the Arrow™ MSB Procedure Kit features the Arrowg+ard Blue Plus™ CVC, the only full-spectrum antimicrobial CVC that protects against gram-positive, gram-negative bacteria and fungi, the key infectious pathogens responsible for CLABSI4. Alongside essential components for the placement of Centrally-Inserted Central Catheters, including those for taking maximal sterile barrier precautions, this all-in-one solution supports clinicians in adhering to national and international guidelines, as well as other authoritative recommendations for reducing CLABSI:

• Centers for Disease Control and Prevention (CDC) Category 1A & 1B recommendations⁶
• Society for Hospital Epidemiology of America (SHEA) Guidelines⁷
• Infusion Nursing Society (INS) Standards of Practice⁸
• Occupational Health and Safety Administration (OSHA) Bloodborne Pathogens Standard⁹
• European Society of Anesthesiology Guidelines¹⁰

By aligning with these national and international guidelines and recommendations, Teleflex continues to aim for the highest standards in medical technology, putting the needs of healthcare providers and the welfare of patients at the forefront of its innovations.

About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Plus, GlideWheel, Deknatel, GlideWheel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2024 Teleflex Incorporated. All rights reserved. MCI-101920.

References:

1. Raad, II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infection Control and Hospital Epidemiology. 1994;15(4 Pt 1): 231-238.
2. In bench testing. Data on file at Teleflex. Test data may not be indicative of clinical performance.
3. iData Research Inc., 2023
4. Spangler D and Moss S. In-Vitro Assessment of Antimicrobial Activity of Three Commercially Available Central Venous Catheters. Poster by Arrow International LLC (Teleflex) Department of Applied Research. Sponsored by Arrow International LLC (Teleflex) 2010-0406 v1
5. https://www.ecdc.europa.eu/sites/default/files/documents/healthcare-associated-point-prevalence-survey-acute- care-hospitals-2022-2023.pdf
6. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011 (Revised 2017). 2. Atlanta, GA: Centers for Disease Control and Prevention; 2017.
7. Buetti N, Marschall J, Drees M, Fakih M, et al. Strategies to Prevent Central Line–Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology. 2022;43 (5): 553-569.
8. Nickel, Barbara, Lisa Gorski, Tricia Kleidon, Amy Kyes, Michelle DeVries, Samantha Keogh, Britt Meyer et al. Infusion Therapy Standards of Practice. Journal of Infusion Nursing. 2024.
9. Occupational Safety & Health Administration Regulations (Standards – 29 CFR). Part 1910.1030: Bloodborne pathogens. Occupational Safety & Health Administration Web site. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030. Accessed on February 12, 2020.
10. Lamperti M, Biasucci DG, Disma N, Pittiruti M, Breschan C, Vailati D, Subert M, Traškaitė V, Macas A, Estebe JP, Fuzier R. European Society of Anaesthesiology guidelines on peri-operative use of ultrasound-guided for vascular access (PERSEUS vascular access). European Journal of Anaesthesiology| EJA. 2020; 37 (5): 344-76.

RX only
Contradiction
The Arrowg+ard Blue Plus™ CVC is contraindicated for patients with known hypersensitivity to chlorhexidine and silver sulfadiazine and/or sulfa drugs.

Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836